|Bid||129.52 x 100|
|Ask||132.85 x 100|
|Day's Range||129.48 - 131.02|
|52 Week Range||120.90 - 148.32|
|PE Ratio (TTM)||276.40|
|Earnings Date||Apr 17, 2018|
|Forward Dividend & Yield||3.36 (2.59%)|
|1y Target Est||150.86|
We have a different kind of market where you must know the SYMBOLS and know what the companies do that are the symbols.
NEW YORK, Feb. 22, 2018-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors ...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Johnson & Johnson securities during the period between February 22, 2013 and February 7, 2018, inclusive .
ohnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
When investors think of dividend stocks, pharmaceutical and biotech companies aren’t usually front of mind. Even though drugs are relatively non-cyclical, these stocks are subjected to high regulatory risks. However,Read More...
The Johnson & Johnson Human Performance Institute (JNJ) in Lake Nona has gotten a building permit from the city of Orlando to begin vertical construction on its $18 million expansion in Lake Nona. The Johnson & Johnson Human Performance Institute does research and provides services for Fortune 500 companies and North American corporations related to mental, physical and spiritual health and well being. The Feb. 8 permit is for the facility to start on new construction of a one-story institutional building, which will house the institute’s performance training center and serve as the hub of the firm's research and development for science-based high performance and energy management.
The following statement is being issued by Levi & Korsinsky, LLP:
Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.
NEW BRUNSWICK, N.J. , Feb. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13 , at The Boston Marriott Copley Place, ...
Law Offices of Howard G. Smith continues its investigation on behalf of Johnson & Johnson Investors investors concerning the Company and its officers’ possible violations of federal securities laws.
NEW YORK, Feb. 20, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Johnson & Johnson between February ...
NEW YORK, Feb. 20, 2018-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Johnson & Johnson and certain of its officers, ...
BSX Stock Recovers after a Robust 4Q17: What's to Come? In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform, with most US healthcare companies reporting one-time financial effects on their balance sheets.
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.